Pipeline and Programs
Pipeline
PROGRAM
DISCOVERY
PRECLINICAL
IND-ENABLING
PHASE 1
PHASE 2
PHASE 3
RIGHTS
OC-1/ALE1
OC-3
CDK7
Worldwide
OC-1/ALE1 for hypophosphatasia
OC-1/ALE1 is a first-in-class, orally bioavailable small molecule for hypophosphatasia. 1cBio entered into a worldwide licensing agreement with Alesta Therapeutics for the development and commercialization of OC-1/ALE1 in December 2024 and is entitled to traditional milestones and royalties, as well as equity ownership in Alesta and monthly compensation for FTE support.
OC-3 for prostate, ovarian and breast cancers
OC-3 is a potentially best-in-class, next generation PARP1-selective inhibitor that aims to maximize efficacy and avoid significant hematologic toxicities exhibited by non-selective PARP inhibitors. OC-3 is a potent PARP1 inhibitor with moderate PARP1 trapping and is predicted to be PARP2 sparing at therapeutic exposures. 1cBio is seeking regional partnerships to support the clinical development of OC-3.
CDK7 inhibitors for solid tumors
We are exploring multiple modalities towards CDK7 inhibition. Our inhibitors are effective against parental, as well as drug-resistant cancer cell lines. Excitingly, we have discovered a potent and brain penetrant CDK7 inhibitor that works across breast cancer phenotypes, including palbociclib-resistant breast cancer, and could revolutionize the treatment paradigm for breast cancer patients with brain metastasis.
Selective PARP1 Inhibitors
-
PARP1 inhibitors can be effective oncology agents, but bone marrow toxicities limit their use
-
They can be used as single agents or in combination with some drugs (e.g., TALZENNA® + XTANDI® for prostate cancer) but not others (e.g., platinum-based chemotherapy for ovarian cancer)
-
PARP inhibitors with reduced bone marrow toxicities have the potential to be used as single agents and in combination with other complementary therapies
-
Preclinical studies studies indicate that PARP2 inhibition promotes bone marrow toxicities, suggesting agents having selectivity for PARP1 at relevant therapeutic concentrations would be safer to use
OC-3 PARylation Activity in WT and PARP-KO Cells
